31.07.19: Not intended for U.S. and UK Media

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancerDarolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADTmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news